IL-2-话题@MedSci

#IL-2#

62篇内容 | 1299人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性, objectType=article, longId=196440, objectId=917e19644006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=917e19644006, replyNumber=0, likeNumber=36, createdTime=2020-06-26, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=917e19644006, moduleTitle=Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917e19644006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626061, encodeId=4510162606152, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, objectType=article, longId=196065, objectId=c775196065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c775196065fc, replyNumber=0, likeNumber=0, createdTime=2020-06-19, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c775196065fc, moduleTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c775196065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626060, encodeId=92c816260604f, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=25, createdTime=2020-06-15, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626059, encodeId=cba8162605970, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=NAT COMMUN：TGF-β信号促进IL-22的产生，从而促进结肠癌的产生, objectType=article, longId=194918, objectId=184e194918da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=184e194918da, replyNumber=0, likeNumber=41, createdTime=2020-05-30, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=184e194918da, moduleTitle=NAT COMMUN：TGF-β信号促进IL-22的产生，从而促进结肠癌的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=184e194918da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Blood：补充IL-2可改善特发性再生障碍性贫血患者预后, objectType=article, longId=193373, objectId=64131933e3b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64131933e3b3, replyNumber=0, likeNumber=45, createdTime=2020-05-03, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64131933e3b3, moduleTitle=Blood：补充IL-2可改善特发性再生障碍性贫血患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64131933e3b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626057, encodeId=4e23162605eaa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=22, createdTime=2020-04-30, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626056, encodeId=70611626056be, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=22, createdTime=2020-02-17, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626055, encodeId=bcea1626055cf, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Cell Death Dis：XBP1-IL-24轴可消除肝细胞毒性未折叠蛋白反应, objectType=article, longId=187773, objectId=c2e418e77305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e418e77305, replyNumber=0, likeNumber=34, createdTime=2020-02-11, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e418e77305, moduleTitle=Cell Death Dis：XBP1-IL-24轴可消除肝细胞毒性未折叠蛋白反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e418e77305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626054, encodeId=3ff91626054ae, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, objectType=article, longId=187183, objectId=a1b618e18333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b618e18333, replyNumber=0, likeNumber=33, createdTime=2020-02-03, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b618e18333, moduleTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b618e18333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626053, encodeId=4fe9162605308, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND, objectType=article, longId=186910, objectId=229d18691054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=229d18691054, replyNumber=0, likeNumber=27, createdTime=2020-01-30, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=229d18691054, moduleTitle=FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=229d18691054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626052, encodeId=e25f1626052e9, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=27, createdTime=2020-01-18, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626051, encodeId=af0a1626051f0, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, objectType=article, longId=181828, objectId=a684181828c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a684181828c3, replyNumber=0, likeNumber=25, createdTime=2019-10-25, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a684181828c3, moduleTitle=强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a684181828c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626050, encodeId=3b4d1626050de, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=24, createdTime=2019-10-23, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626049, encodeId=54a016260496b, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=23, createdTime=2019-10-07, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626048, encodeId=0d3816260489e, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=36, createdTime=2019-08-12, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626047, encodeId=986e162604e9b, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=31, createdTime=2019-07-15, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626046, encodeId=86711626046bf, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=26, createdTime=2019-06-04, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626045, encodeId=8ac91626045ce, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, objectType=article, longId=166678, objectId=b3b81666e8fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b81666e8fb, replyNumber=0, likeNumber=36, createdTime=2019-05-25, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b81666e8fb, moduleTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b81666e8fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626044, encodeId=829c16260447a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关, objectType=article, longId=166433, objectId=55eb166433ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55eb166433ae, replyNumber=0, likeNumber=34, createdTime=2019-05-22, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55eb166433ae, moduleTitle=EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55eb166433ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=38, createdTime=2019-03-03, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-2

2020-05-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性

2020-06-26

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎

2020-06-19

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-06-15

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

NAT COMMUN：TGF-β信号促进IL-22的产生，从而促进结肠癌的产生

2020-05-30

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Blood：补充IL-2可改善特发性再生障碍性贫血患者预后

2020-05-03

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2020-04-30

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-02-17

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Cell Death Dis：XBP1-IL-24轴可消除肝细胞毒性未折叠蛋白反应

2020-02-11

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

2020-02-03

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND

2020-01-30

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-01-18

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

强生向欧洲药品管理局提交申请，寻求扩大其IL-23单抗Tremfya用于治疗银屑病关节炎

2019-10-25

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2019-10-23

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-10-07

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2019-08-12

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2019-07-15

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2019-06-04

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验

2019-05-25

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

2019-05-22

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

科室
- - 订阅+
  - 更多科室
工具
服务